Healthcare / BiotechnologyNasdaqGM
$41.69
-0.02 (-0.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-17.9M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$523M
P/E
26.6x
↑EV/EBITDA
16.7x
↑ROE
37.8%
↑Gross Margin
N/A
•Debt/Equity
1.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
-12.5%
FCF CAGR
—
FCF margin
-153.1%
FCF / Net income
-0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.7M · net income $31.7M · FCF $-17.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $11.7M | $11.7M | $10.2M | $4.8M | $6.0M | $36.5M | $27.9M | $17.3M | $5.1M | $52.4M | $5.6M | $55.4M | $18.9M | $35.5M | $33.8M | $58.2M | $33.6M | $98.4M |
| Net Income | $31.7M | $31.7M | $-13.8M | $-40.8M | $-17.1M | $15.8M | $13.3M | $-2.0M | $-13.3M | $14.6M | $-53.5M | $-20.6M | $-38.3M | $-124.1M | $-71.1M | $-32.7M | $-68.8M | $550000.00 |
| EBITDA | $47.8M | $47.8M | $-5.4M | $-39.4M | $-17.0M | — | $12.4M | $-3.9M | $-16.8M | $17.3M | $-60.8M | $-38.2M | $-79.9M | $-55.3M | $-52.5M | $-28.6M | $-61.4M | $19.8M |
| EPS | 1.46 | 1.46 | -1.65 | -4.04 | -1.98 | 0.65 | 0.78 | -0.23 | -1.59 | 0.73 | -8.89 | -3.50 | -13.49 | -28.60 | -22.00 | — | — | — |
| Operating Margin | 97.6% | 97.6% | -391.2% | -493.1% | -288.9% | 48.0% | 44.4% | -22.5% | -332.6% | 32.5% | -1106.4% | -71.6% | -433.8% | -164.2% | -167.6% | -58.3% | -199.5% | 13.2% |
| Net Margin | 272.0% | 272.0% | -135.2% | -858.2% | -283.8% | 43.3% | 47.6% | -11.5% | -263.3% | 27.8% | -962.1% | -37.2% | -203.0% | -349.9% | -210.4% | -56.3% | -204.4% | 0.6% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 1.57 | 1.57 | 1.93 | 1.40 | 0.00 | — | 0.15 | 0.62 | 1.15 | 2.52 | -0.54 | -18.52 | 5.26 | -8.82 | 1.75 | 2.23 | 0.58 | — |
| Current Ratio | 3.59 | 3.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-17.9M | $-17.9M | $-13.8M | $-18.2M | $-28.1M | — | $10.1M | — | $-12.7M | $2.7M | — | — | — | $-47.1M | $-43.3M | $-32.4M | $-52.9M | $7.2M |
| Returns | ||||||||||||||||||
| ROE | 37.8% | 37.8% | -22.3% | -46.0% | -13.8% | 11.1% | 15.4% | -4.5% | -71.0% | 252.3% | 113.4% | 892.4% | -1235.9% | 3111.6% | -331.0% | -218.1% | -291.5% | 3.1% |
| Valuation | ||||||||||||||||||
| P/E | 26.55 | 26.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 16.69 | 16.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 8.93 | 8.93 | 5.07 | 2.70 | 2.03 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 14.1% | 14.1% | 114.8% | -21.1% | — | 30.7% | 61.7% | 240.9% | -90.3% | 842.3% | -90.0% | 193.9% | -46.8% | 4.9% | -42.0% | 73.0% | -65.8% | — |
| EPS Growth | 188.5% | 188.5% | 59.2% | -104.0% | — | -16.7% | 439.1% | 85.5% | -317.8% | 108.2% | -154.0% | 74.1% | 52.8% | -30.0% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.3%
EPS terminal req.
$3.70
Spread vs growth
152.2%
5Y implied EPS CAGR
25.1%
EPS terminal req.
$4.48
Spread vs growth
163.4%
10Y implied EPS CAGR
17.3%
EPS terminal req.
$7.21
Spread vs growth
171.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+68.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.65 → 1.46
Residual
+68.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.